Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: Evaluating the impact of baseline severity

Alzheimer's Research and Therapy

Volumn 5, Issue 1, 2013, Pages

  Ferris, Steven ^a   Cummings, Jeffrey ^b   Christensen, Daniel ^c   Doody, Rachelle ^d   Farlow, Martin ^e   Sabbagh, Marwan ^f   Liu, Liang ^g   MacKell, Joan ^h   Fain, Randi ^g  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b CLEVELAND CLINIC LOU RUVO CENTER FOR BRAIN HEALTH   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f SUN HEALTH RESEARCH INSTITUTE   (United States)

^g EISAI INC   (United States)

^h PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL;

AGED; ALZHEIMER DISEASE; ARTICLE; ATTENTION; COGNITION; COHORT ANALYSIS; CONTROLLED STUDY; DEPTH PERCEPTION; DESCRIPTIVE RESEARCH; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; FEMALE; HUMAN; LANGUAGE; MAJOR CLINICAL STUDY; MALE; MEMORY; MINI MENTAL STATE EXAMINATION; PARALLEL DESIGN; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

EID: 84874001601     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt166     Document Type: Article

References (22)

1. 2012 Alzheimer's disease facts and figures. http://www.alz.org/downloads/ facts-figures-2012.pdf
2. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA, Arch Neurol 2003 60 1119 1122 10.1001/archneur.60.8.1119 12925369 (Pubitemid 36975801)
3. Memantine in moderate-to-severe Alzheimer's disease. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ, N Engl J Med 2003 348 1333 1341 10.1056/NEJMoa013128 12672860 (Pubitemid 36384100)
4. Cognition, function, and caregiving time patterns in patients with mild-to-moderate Alzheimer disease: a 12-month analysis. Feldman HH, Van BB, Kavanagh SM, Torfs KE, Alzheimer Dis Assoc Disord 2005 19 29 36 10.1097/01.wad.0000157065.43282.bc 15764869 (Pubitemid 40488661)
5. A new rating scale for Alzheimer's disease. Rosen WG, Mohs RC, Davis KL, Am J Psychiatry 1984 141 1356 1364 6496779
6. Alzheimer's Disease Assessment Scale: the validation of the scale in Greece in elderly demented patients and normal subjects. Tsolaki M, Fountoulakis K, Nakopoulou E, Kazis A, Mohs RC, Dement Geriatr Cogn Disord 1997 8 273 280 10.1159/000106644 9298628 (Pubitemid 27344869)
7. Measuring cognition in advanced Alzheimer's disease for clinical trials. Schmitt FA, Cragar D, Ashford JW, Reisberg B, Ferris S, Mobius HJ, Stoffler A, J Neural Transm Suppl 2002 135 148 (Pubitemid 37046661)
8. Severe impairment battery. A neuropsychological test for severely demented patients. Panisset M, Roudier M, Saxton J, Boller F, Arch Neurol 1994 51 41 45 10.1001/archneur.1994.00540130067012 8274108 (Pubitemid 24020169)
9. Assessment of the severely impaired patient: description and validation of a new neuropsychological test battery. Saxton J, McGonigle-Gibson KL, Swihart AA, Miller VJ, Boller F, Psychol Assess 1990 2 298 303
10. Development of a short form of the Severe Impairment Battery. Saxton J, Kastango KB, Hugonot-Diener L, Boller F, Verny M, Sarles CE, Girgis RR, Devouche E, Mecocci P, Pollock BG, DeKosky ST, Am J Geriatr Psychiatry 2005 13 999 1005 16286444 (Pubitemid 46638667)
11. The Severe Impairment Battery: concurrent validity and the assessment of longitudinal change in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Schmitt FA, Ashford W, Ernesto C, Saxton J, Schneider LS, Clark CM, Ferris SH, Mackell JA, Schafer K, Thal LJ, Alzheimer Dis Assoc Disord 1997 11 (Suppl 2):S51 S56
12. Pooled analyses on cognitive effects of memantine in patients with moderate to severe Alzheimer's disease. Emre M, Mecocci P, Stender K, J Alzheimers Dis 2008 14 193 199 18560130 (Pubitemid 352040033)
13. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Schmitt FA, van Dyck CH, Wichems CH, Olin JT, Alzheimer Dis Assoc Disord 2006 20 255 262 10.1097/01.wad.0000213860.35355.d4 17132970 (Pubitemid 44900939)
14. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I, JAMA 2004 291 317 324 10.1001/jama.291.3.317 14734594 (Pubitemid 38101604)
15. Donepezil treatment in severe Alzheimer's disease: a pooled analysis of three clinical trials. Winblad B, Black SE, Homma A, Schwam EM, Moline M, Xu Y, Perdomo CA, Swartz J, Albert K, Curr Med Res Opin 2009 25 2577 2587 19735164
16. Aricept [package insert]. Teaneck, NJ: Eisai Inc 2006
17. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: a 24-week, randomized, double-blind study. Farlow MR, Salloway S, Tariot PN, Yardley J, Moline ML, Wang Q, Brand-Schieber E, Zou H, Hsu T, Satlin A, Clin Ther 2010 32 1234 1251 10.1016/j.clinthera.2010.06.019 20678673
18. Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease. Ferris SH, Schmitt FA, Saxton J, Richardson S, Mackell J, Sun Y, Xu Y, Alzheimers Res Ther 2011 3 22 10.1186/alzrt84 21689411
19. Cholinergic markers in elderly patients with early signs of Alzheimer disease. Davis KL, Mohs RC, Marin D, Purohit DP, Perl DP, Lantz M, Austin G, Haroutunian V, JAMA 1999 281 1401 1406 10.1001/jama.281.15.1401 10217056 (Pubitemid 29190218)
20. Effect of donepezil on cognition in severe Alzheimer's disease: a pooled data analysis. Cummings J, Jones R, Wilkinson D, Lopez O, Gauthier S, Waldemar G, Zhang R, Xu Y, Sun Y, Richardson S, Mackell J, J Alzheimers Dis 2010 21 843 851 20634594
21. Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial. Burns A, Bernabei R, Bullock R, Cruz Jentoft AJ, Frolich L, Hock C, Raivio M, Triau E, Vandewoude M, Wimo A, Came E, Van BB, Hammond GL, van Oene JC, Schwalen S, Lancet Neurol 2009 8 39 47 10.1016/S1474-4422(08)70261-8 19042161
22. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies. Mecocci P, Bladstrom A, Stender K, Int J Geriatr Psychiatry 2009 24 532 538 10.1002/gps.2226 19274640